More important, high expression of PICOT and low expression of CCND2 correlated with poor patient survival in five different types of human cancers, namely lung and pancreatic adenocarcinoma, glioblastoma, and breast and esophageal cancer. Here, GLRX3 is linked to esophageal cancer.